申请人:Nanjing Transthera Biosciences Co., Ltd.
公开号:US20210177828A1
公开(公告)日:2021-06-17
The present invention provides a novel inhibitor compound of general formula (I), exhibiting excellent kinase inhibitor activity. The compound of the present invention can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or ligands thereof. In addition, the compound of the present invention can also target CSF1R kinase, and thus can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or CSF1R kinase receptors and/or ligands thereof.